Genmab has acquired 2 companies, including 2 in the last 5 years.
Genmab’s largest acquisition to date was in 2025, when it acquired Merus BV for $8.0B. Genmab has acquired in 1 US state, and 2 countries. The Company’s most targeted sectors include life science (100%).
| Date | Target |
Value
$mlns |
Transaction Type | Acquirer | Seller |
SRC
Link |
|---|---|---|---|---|---|---|
| 2025-09-29 |
Merus · Life Science
Utrecht, Netherlands · www.merus.nl Merus BV is a fully-integrated biotechnology company developing cancer therapeutics that combine the benefits of monoclonal antibodies with the ability of simultaneously addressing multiple targets. Merus was founded in 2003 and is based in Utercht, Netherlands. Advisors: Jefferies , Latham & Watkins , NautaDutilh |
8,000 | Add-on Acquisition |
Genmab
|
- |
Unlimited Searches Unlimited Profile Views Build and Export Lists of
Mergr is a user-friendly database designed to simplify the complex world of private equity and M&A for busy professionals.
We created Mergr to eliminate the challenge of tracking company acquisitions, sales, and ownership, providing clear insights into investment firms and their activities. For example, explore an investment firm’s investment criteria, deal history, portfolio, and connections - organized to help you uncover opportunities and make informed decisions.
With Mergr, gain access to a comprehensive, interconnected web of transactions, investors, companies, and advisors - all in one place.
Full access to Mergr's investor, acquirer, and transaction data starts here.
